Explore the various ways to “Ask Lilly.” This includes our website for healthcare professionals that shares our scientific presentations, publications, and educational materials. We’re here to help!

Attention STAR Annual Meeting attendees! Join Dr. Bakewell & Dr. Hsueh for “The Dual Challenge of Inflammation in Obesity and Psoriatic Arthritis” Sat, Feb 22, at 6:30-8:00 PM CST in the Escondido 1-3 rooms at the Gaylord Texan Resort. View program here:

Hello #AAAAI25 Attendees! Join Dr. Bob Geng, MD & Dr. Marc Serota, MD for “Taking Aim at AD with IL-13 Targeted Therapies” on Sunday, Mar. 2, at 7:00 -7:45am in the Grand Ballroom Salon 5 at the Marriot Marquis. View congress page here: #AtopicDermatitis

New Publication Alert! Read the latest results on patient-reported outcomes across EASI categories in #atopicdermatitis patients treated with anti-IL13 therapy from the ADvocate 1 & 2 trials. Now available here in the Journal of Dermatological Treatment:

Only 8% of eligible #AtopicDermatitis (AD) patients receive systemic therapy. Discover how our Guide to Systemic Therapy can help AD experts determine a patient’s eligibility for systemic therapies. View the guide here:

Attention #CCCongress25 attendees! Join our presentation, “Here Come the IL-23p19 Inhibitors: Exploring New Treatments in IBD” with Dr. Vipul Jairath & Dr. Aline Charabaty in the Golden Gate A room at 7:00 PM PST on Feb 6th. CCC registration: #GITwitter

Hello #CCCongress25 attendees! The Lilly GI team is excited to engage with you and explore the latest #IBD research at CCC. Visit us at Booth 1014. HCP attendees can learn more here: #GITwitter

New Publication Alert! Newly published analysis from the ADvocate 1 & 2 clinical trials outlines the results of continued long-term anti-IL13 treatment in atopic dermatitis patients in the Journal of the American Academy of Dermatology. Read more here:

Hello #MauiDerm Attendees! Join Dr. Alexandra Golant, MD, for “Antibody Therapies in Atopic Dermatitis" on Wednesday, January 22nd, from 6:30 to 7:00AM in Haleakala Ballroom at the Grand Wailea. Register here: #AtopicDerm

Explore our ConnectAD™️ clinical cases which highlight individualized approaches to detection and diagnosis of Alzheimer’s disease. In some clinical cases you can access content specific to treatment and monitoring. Explore Now:

Curious about the role of neuroimaging in the diagnosis and monitoring of treatment in Alzheimer's Disease? Join us for a discussion at #ASN2025 in Dallas, TX on January 17th from 12:15PM – 1:15PM CST! Learn more here: #Alzheimers

The results of the Phase 3 BRAVE-AA2 sub-study on down-titrating a JAK inhibitor to week 152 in patients with severe #AlopeciaAreata are now published in the Journal of the American Academy of Dermatology. View publication here:

Attention #AIBD2024! Don’t miss our presentation, “How Does Inflammation Drive Assessment in Crohn’s Disease?” with Miguel Regueiro, MD, and David Rubin, MD, FACG. Join us in the Northern Hemisphere Ballroom C at 6:30 AM EST on Dec. 11th. Learn more:

Mount Sinai Winter Symposium Attendees! Join Dr. Emma Guttman-Yassky, MD, PhD for "New Developments in Atopic Dermatitis" on Friday, December 13, from 4:00 to 4:30pm in Conference Room 20 at the New York Academy of Medicine. View agenda here: #AtopicDerm

The Lilly GI Team is excited to attend #AIBD2024 in Orlando, FL! Visit Lilly Medical at Booth 516, where our team will be available to answer your questions. View the schedule here: #InflammatoryBowelDisease #GITwitter

Lilly Medical is proud to stand alongside healthcare professionals making meaningful progress for people with #diabetes! Thank you to our dedicated #HCPs for being true champions of care and hope. Learn More:

New Publication! Explore the latest science in #Obesity from the SURMOUNT-1 Phase 3 trial, now available in the New England Journal of Medicine. Read the results in NEJM:

New Publication in Neurology and Therapy: Factors and Reasons Associated with Hesitating to Seek Care for Migraine. To explore the results of the OVERCOME (US) Study, read the full publication here:

Lilly Medical thanks you for joining us at #ACR2024! Hear what Lilly's Sr. Vice President of Immunology Global Medical Affairs, Anabela Cardoso MD, has to say about their experience! Stay connected to the latest science - click here to learn more:

In The Lancet medical journal: Efficacy & safety results from the VIVID-1 Phase 3 study evaluating patients with moderately to severely active #CrohnsDisease with a p19-directed antibody against interleukin-23. View publication:

Did you know the majority of patients with psoriatic arthritis (#PsA) and axial spondyloarthritis (#axSpA) experience at least one comorbidity? Learn more about the common comorbidities associated with these conditions here: #PsoriaticArthritis